Vice President
Kymera
Arsalan Qazi Shabbir, M.D., Ph.D., is a distinguished clinical development leader with expertise in immunology and inflammation. As Vice President and Therapeutic Area Head of Immunlogy Clinical Development at Kymera Therapeutics, he oversees programs spanning dermatology, respiratory, gastroenterology, and rheumatology, guiding therapies from translational research to late-stage clinical trials. Renowned for driving innovative clinical strategies and biomarker development, Dr. Shabbir ensures alignment with regulatory and commercialization goals to optimize patient outcomes.
Previously, Dr. Shabbir held key roles at Regeneron and AbbVie, where he led the clinical development of groundbreaking therapies such as dupilumab, risankizumab, adalimumab, and upadacitinib, achieving pivotal regulatory milestones and advancing treatments for numerous indications. A co-founder of Aegle Therapeutics, he pioneered regenerative medicine innovations using stem cell-derived therapies. With an M.D. and Ph.D. from the University at Buffalo and a prolific record of publications, Dr. Shabbir combines clinical expertise with strategic vision to drive transformative advances in patient care.
Disclosure information not submitted.
KT-621: First STAT6-Targeted Medicine in Clinical Development
Thursday, June 26, 2025
11:00am - 11:30am East Coast USA Time
